Teva Pharmaceuticals shares are trading higher after UBS upgraded the stock from Neutral to Buy and raised its price target from $11 to $13.
Portfolio Pulse from Benzinga Newsdesk
Teva Pharmaceuticals' stock (TEVA) has seen an increase in its trading price following an upgrade from UBS, which changed its rating from Neutral to Buy and increased the price target from $11 to $13.
November 27, 2023 | 2:53 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Teva Pharmaceuticals' stock is experiencing a positive impact after UBS upgraded the stock to Buy from Neutral and raised the price target to $13 from $11.
Analyst upgrades typically lead to a positive short-term reaction in the stock market as they suggest a better-than-previously-expected future performance of the company. The increase in price target further reinforces the positive outlook, indicating that UBS analysts see more value in the stock than before.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100